Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury

Deborah M. Stein, Allison L. Lindell, Karen R. Murdock, Joseph A. Kufera, Jay Menaker, Grant V. Bochicchio, Bizhan Aarabi, Thomas M. Scalea

Research output: Contribution to journalArticlepeer-review

Abstract

The management of severe traumatic brain injury (TBI) focuses on prevention and treatment of secondary insults such as cerebral hypoxia (CH). There are a number of biomarkers that are thought to play a part in secondary injury following severe TBI. This study evaluates the association between S100β, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP), detected in the serum of severe TBI patients and CH as measured by brain tissue oxygen partial pressure (Pbo 2). Patients with severe TBI were prospectively enrolled. Pressure times time (PTD; mm Hg*h), measuring the depth and duration of CH, was calculated for 12-h periods for episodes of moderate (Pbo 2 <20mm Hg) and severe (Pbo 2 <15mm Hg) CH, and compared to serum levels of S100β, NSE, and GFAP drawn prior to periods of monitoring. An adjusted mixed model analysis was applied as was receiver operating characteristic (ROC) curve analysis. Of 76 patients enrolled, 24 had Pbo 2 monitoring. One hundred and thirty serum samples were matched with 12-h periods of monitoring. Significant associations were found in adjusted analyses between increasing serum levels of S100β (coefficient=0.57, 0.56; p22

Original languageEnglish (US)
Pages (from-to)1140-1149
Number of pages10
JournalJournal of Neurotrauma
Volume29
Issue number6
DOIs
StatePublished - Apr 10 2012
Externally publishedYes

Keywords

  • biomarkers
  • clinical management of CNS injury
  • traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury'. Together they form a unique fingerprint.

Cite this